Prabesh Bajracharya1, Amrish Jain1, Rossana Baracco1, Tej K Mattoo1, Gaurav Kapur2. 1. Children's Hospital of Michigan, Wayne State University, 3901 Beaubien Boulevard, Detroit, MI, 48201, USA. 2. Children's Hospital of Michigan, Wayne State University, 3901 Beaubien Boulevard, Detroit, MI, 48201, USA. gkapur@med.wayne.edu.
Abstract
BACKGROUND: Patients negative for Shiga toxin-producing E. coli (STEC) are categorized as having atypical hemolytic uremic syndrome (HUS) and are associated with an increased risk for complement mutations and poorer prognosis compared with typical HUS. However, STEC identification is limited by the natural history of HUS. METHODS: The current study is aimed at identifying HUS patients with poor outcomes based on the presence or absence of diarrhea (D) or Shiga toxin (S). A single-center retrospective review (2003-2012) of 42 HUS patients (follow-up 31.3 ± 38.7 months) was carried out. HUS was managed clinically with supportive treatments such as dialysis, plasma therapy, and eculizumab. RESULTS: There was no significant difference in the D+S+ (31 %), D+S- (50 %) and D-S- (19 %) groups in the outcome variables of chronic kidney disease stages I-II (100 % vs 81 % vs 67 %) and proteinuria at follow-up (20 % vs 12.5 % vs 33.3 %), hospitalization duration (16.0 ± 8.7 vs 18.1 ± 9.5 vs 23.7 ± 12.9 days); dialysis requirement (50 % vs 81 % vs 66.7 %), and dialysis duration (10.2 ± 1.9 vs 33.3 ± 72.8 vs 10.3 ± 8.1 days). There was no significant difference in study outcomes in STEC+ (59 %) versus STEC- (41 %) groups. Genetic testing was performed in 12 % of HUS patients based on age, recurrent HUS, familial HUS, persistently low C3, or prolonged dialysis, and 80 % of the patients tested were positive for genetic mutations. CONCLUSIONS: Our study does not show poorer outcomes in STEC- HUS. Indications and the cost-effectiveness of genetic testing, eculizumab, and plasmapheresis in STEC- HUS need to be evaluated further.
BACKGROUND:Patients negative for Shiga toxin-producing E. coli (STEC) are categorized as having atypical hemolytic uremic syndrome (HUS) and are associated with an increased risk for complement mutations and poorer prognosis compared with typical HUS. However, STEC identification is limited by the natural history of HUS. METHODS: The current study is aimed at identifying HUSpatients with poor outcomes based on the presence or absence of diarrhea (D) or Shiga toxin (S). A single-center retrospective review (2003-2012) of 42 HUSpatients (follow-up 31.3 ± 38.7 months) was carried out. HUS was managed clinically with supportive treatments such as dialysis, plasma therapy, and eculizumab. RESULTS: There was no significant difference in the D+S+ (31 %), D+S- (50 %) and D-S- (19 %) groups in the outcome variables of chronic kidney disease stages I-II (100 % vs 81 % vs 67 %) and proteinuria at follow-up (20 % vs 12.5 % vs 33.3 %), hospitalization duration (16.0 ± 8.7 vs 18.1 ± 9.5 vs 23.7 ± 12.9 days); dialysis requirement (50 % vs 81 % vs 66.7 %), and dialysis duration (10.2 ± 1.9 vs 33.3 ± 72.8 vs 10.3 ± 8.1 days). There was no significant difference in study outcomes in STEC+ (59 %) versus STEC- (41 %) groups. Genetic testing was performed in 12 % of HUSpatients based on age, recurrent HUS, familial HUS, persistently low C3, or prolonged dialysis, and 80 % of the patients tested were positive for genetic mutations. CONCLUSIONS: Our study does not show poorer outcomes in STEC- HUS. Indications and the cost-effectiveness of genetic testing, eculizumab, and plasmapheresis in STEC- HUS need to be evaluated further.
Authors: Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer Journal: N Engl J Med Date: 2011-05-25 Impact factor: 91.245
Authors: N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl Journal: Kidney Int Date: 2006-06-14 Impact factor: 10.612
Authors: Howard Trachtman; Avital Cnaan; Erica Christen; Kathleen Gibbs; Sanyi Zhao; David W K Acheson; Robert Weiss; Frederick J Kaskel; Adrian Spitzer; Gladys H Hirschman Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat Journal: N Engl J Med Date: 2013-06-06 Impact factor: 91.245
Authors: Rajal K Mody; Ruth E Luna-Gierke; Timothy F Jones; Nicole Comstock; Sharon Hurd; Joni Scheftel; Sarah Lathrop; Glenda Smith; Amanda Palmer; Nancy Strockbine; Deborah Talkington; Barbara E Mahon; Robert M Hoekstra; Patricia M Griffin Journal: Arch Pediatr Adolesc Med Date: 2012-10
Authors: Dineke Westra; Katherine A Vernon; Elena B Volokhina; Matthew C Pickering; Nicole C A J van de Kar; Lambert P van den Heuvel Journal: J Hum Genet Date: 2012-05-24 Impact factor: 3.172
Authors: Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat Journal: Kidney Int Date: 2015-02-04 Impact factor: 10.612
Authors: Omar Cabarcas-Barbosa; Gustavo Aroca-Martínez; Carlos G Musso; Elizabeth Ramos-Bolaños; Henry González-Tórres; Zilac Espitaleta-Vergara; Alex Domínguez-Vargas; Edufamir Ararat-Rodriguez; José Orozco; Luis Castillo-Parodi; Juan Conde-Manotas; Rodrigo Daza-Arnedo; Víctor Rodríguez-SanJuan; Liliana Gómez-Navarro; Roberto Acosta-Madiedo; Luis Barros-Camargo; Angélica Aduen-Carrillo; Francisco Ayola-Anaya; María Pulgar-Emiliani; Andrés Cadena-Bonfanti Journal: Int Urol Nephrol Date: 2021-10-13 Impact factor: 2.266
Authors: Kioa L Wijnsma; Susan T Veissi; Sheila A M van Bommel; Rik Heuver; Elena B Volokhina; Diego J Comerci; Juan E Ugalde; Nicole C A J van de Kar; Lambertus P W J van den Heuvel Journal: Pediatr Nephrol Date: 2018-10-26 Impact factor: 3.714